Literature DB >> 19800414

Anticancer drug discovery in the future: an evolutionary perspective.

Xianghui Ma1, Zhiwen Wang.   

Abstract

Identification of agents that are pharmacologically active against human cancer has depended largely on the screening of natural products and their analogs. Many anticancer drugs have been discovered fortuitously through random investigation of organisms; indeed, serendipity remains important in anticancer drug discovery. Although it is broadly accepted that cancers comprise an evolutionary microcosm, this idea has not been advanced to understand and control carcinogenic progression. Here, we address anticancer drug discovery from an evolutionary perspective and present a series of case studies that demonstrate that the rate of anticancer drug discovery can be increased greatly by targeted screening of natural compounds from ancient species.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800414     DOI: 10.1016/j.drudis.2009.09.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  19 in total

1.  Evolution of dopamine-related systems: biosynthesis, degradation and receptors.

Authors:  Xianghui Ma; Zhiwen Wang; Xinbo Zhang
Journal:  J Mol Evol       Date:  2010-10-02       Impact factor: 2.395

Review 2.  Modern natural products drug discovery and its relevance to biodiversity conservation.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2010-12-07       Impact factor: 4.050

3.  Hedyotis diffusa willd extract suppresses colorectal cancer growth through multiple cellular pathways.

Authors:  Jianyu Feng; Yiyi Jin; Jun Peng; Lihui Wei; Qiaoyan Cai; Zhaokun Yan; Zijun Lai; Jiumao Lin
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

4.  In vitro anti-proliferative activity of Argemone gracilenta and identification of some active components.

Authors:  Mario Alberto Leyva-Peralta; Ramón Enrique Robles-Zepeda; Adriana Garibay-Escobar; Eduardo Ruiz-Bustos; Laura Patricia Alvarez-Berber; Juan Carlos Gálvez-Ruiz
Journal:  BMC Complement Altern Med       Date:  2015-02-05       Impact factor: 3.659

5.  Chemical composition and inhibitory effects of water extract of Henna leaves on reactive oxygen species, DNA scission and proliferation of cancer cells.

Authors:  Manish Kumar; Madhu Chandel; Paramjeet Kaur; Kritika Pandit; Varinder Kaur; Sandeep Kaur; Satwinderjeet Kaur
Journal:  EXCLI J       Date:  2016-12-21       Impact factor: 4.068

6.  Inducing Apoptosis of Cancer Cells Using Sea Pen Virgularia gustaviana Extract Which is Comparable to Cembrane Diterpene Sarcophine.

Authors:  Sharareh Sharifi; Pargol Ghavam Mostafavi; Ali Mashinchian Moradi; Mohammad Hadi Givianrad; Hassan Niknejad
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 7.  Conifers Phytochemicals: A Valuable Forest with Therapeutic Potential.

Authors:  Kanchan Bhardwaj; Ana Sanches Silva; Maria Atanassova; Rohit Sharma; Eugenie Nepovimova; Kamil Musilek; Ruchi Sharma; Mousa A Alghuthaymi; Daljeet Singh Dhanjal; Marcello Nicoletti; Bechan Sharma; Navneet Kumar Upadhyay; Natália Cruz-Martins; Prerna Bhardwaj; Kamil Kuča
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

8.  The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.

Authors:  Moltira Promkan; Sumana Dakeng; Subhas Chakrabarty; Oliver Bögler; Pimpicha Patmasiriwat
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

9.  Antiproliferative evaluation of isofuranodiene on breast and prostate cancer cell lines.

Authors:  Michela Buccioni; Diego Dal Ben; Catia Lambertucci; Filippo Maggi; Fabrizio Papa; Ajiroghene Thomas; Claudia Santinelli; Gabriella Marucci
Journal:  ScientificWorldJournal       Date:  2014-05-22

10.  Assessment of cytotoxicity and genotoxicity of stem bark extracts from Canarium odontophyllum Miq. (dabai) against HCT 116 human colorectal cancer cell line.

Authors:  Dayang Fredalina Basri; Zafira Ayushah Zainul Alamin; Kok Meng Chan
Journal:  BMC Complement Altern Med       Date:  2016-01-29       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.